DNBC-FINANCIAL-GROUP
13.4.2022 11:24:09 CEST | Business Wire | Press release
Sending money abroad has traditionally been an arduous and expensive task that frustrates users. Plus with the post-pandemic changes, people now need a faster yet cheaper contactless money transfer solution that can be done quickly on a mobile. That leads to the demand for payment apps.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220413005433/en/
But which ones are the best international payment apps ? That depends. The best payment apps are the ones that work best for your business.
DNBCnet App - Powered by the leading Digital Banking Firm DNBC
Digital banking firm DNBC was founded by Le Hung Anh in 2017, professionally known as Jimmy Lee, headquartered in Singapore.
With the mission to support enterprises as well as individuals in financial transactions over the world, DNBC has developed the DNBCnet app in order to make the banking process easier yet cheaper by adapting more innovative changes right on the app.
“DNBCnet is an all-in-one tool for any user who wants to conduct international transactions, manage and control the cash flow of their business,” said Jimmy Lee, Founder & CEO of DNBC.
DNBCnet App offers exceptional benefits
Best for corporate international money transfers
When it comes to international payments , companies just want to make quick transactions while keeping the costs as low as possible.
It can be difficult to find a provider that offers quick transfers and low fees. But if you want to keep your business straightforward, you don’t have to look very far because DNBC business accounts will fit the bill.
“If you structure payments properly, digital banking can create more predictable cash flow over the life of your business,” said CEO Jimmy Lee.
Fastest ways to send money abroad
When sending money globally, an important factor besides fees is the speed. Speedy transfer will accelerate the business, otherwise it will slow down the whole operation significantly.
With DNBCnet app , recipients will get the fund instantly if transferred in DNBC network. It only takes 1-2 business days to send to someone outside the system.
Ease of use
DNBCnet works as a mobile app, the signing up process can be done quickly with a few simple steps. It owns a seamless visual interface which allows users to handle payments in no time.
On top of that, you can keep track of your transfer and get updates along the way, so you’re always in the loop about your funds.
Utmost safety for mobile banking
Security is a must for any financial app . DNBC has raised its standard by adopting the latest technology such as two-factor authentication , data encryption for every transaction.
That will help protect account information and transactions to the fullest extent preventing any potential frauds for customers and businesses.
As a bonus perk
Besides the core function, DNBCnet also adds up a number of accompanying features to make it even more favorable. Users now can also check real-time exchange rate information, view financial statistics by charts, send mobile top up and many more.
Level up your payment practice with DNBCnet app
One of the key benefits of digital banking apps is that they allow users to manage payments anywhere and anytime. With that, business owners can focus on delivering services, not bothering with the payment process .
DNBCnet app offers exceptional convenience and transparency to its users. Via smartphones, you can find the IOS version for mobile banking on the App Store or mobile banking app for Android in the Google Store. Or simply search for DNBCnet .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220413005433/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
